Protein Tyrosine Kinases

From Inhibitors to Useful Drugs

eBook
eBook
Fr. 257.90
Fr. 257.90
inkl. gesetzl. MwSt.
inkl. gesetzl. MwSt.
Sofort per Download lieferbar
Sofort per Download lieferbar
Sie können dieses eBook verschenken  i

Weitere Formate

gebundene Ausgabe

Fr. 311.00

Accordion öffnen
  • Protein Tyrosine Kinases

    Humana Press

    Versandfertig innert 1 - 2 Werktagen

    Fr. 311.00

    Humana Press

eBook (PDF)

Fr. 257.90

Accordion öffnen
  • Protein Tyrosine Kinases

    PDF (Springer)

    Sofort per Download lieferbar

    Fr. 257.90

    PDF (Springer)

Beschreibung

Leading researchers, from the Novartis group that pioneered Gleevec/Glivec(TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.

Produktdetails

Format PDF i
Herausgeber Doriano Fabbro, Frank McCormick
Kopierschutz Ja i
Family Sharing Nein i
Text-to-Speech Ja i
Seitenzahl 290 (Printausgabe)
Erscheinungsdatum 13.11.2007
Sprache Englisch
EAN 9781592599622
Verlag Springer
Dateigröße 20332 KB

Kundenbewertungen

Es wurden noch keine Bewertungen geschrieben.

  • Artikelbild-0
  • Protein Tyrosine Kinases as Targets for Cancer and Other Indications Mark Pearson, Carlos García-Echeverría, and Doriano Fabbro Inhibitors of Signaling Interfaces: Targeting Src Homology 2 Domains in Drug Discovery Carlos García-Echeverría PI3-Kinase Inhibition: A Target for Therapeutic Intervention Peter M. Finan and Stephen G. Ward Src as a Target for Pharmaceutical Intervention: Potential and Limitations Mira Susa, Martin Missbach, Rainer Gamse, Michaela Kneissel, Thomas Buhl, Jürg A. Gasser, Markus Glatt, Terence O'Reilly, Anna Teti, and Jonathan Green Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target in Leukemia Blanca Scheijen and James D. Griffin JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma Renate Burger and Martin Gramatzki Glivec® (Gleevec®, Imatinib, STI571): A Targeted Therapy for Chronic Myelogenous Leukemia Elisabeth Buchdunger and Renaud Capedeville Platelet-Derived Growth Factor: Normal Function, Role in Disease, and Application of PDGF Antagonists Tobias Sjöblom, Kristian Pietras, Arne Östman, and Carl-Henrik Heldin Structural Biology of Protein Tyrosine Kinases Sandra W. Cowan-Jacob, Paul Ramage, Wilhelm Stark, Gabriele Fendrich, and Wolfgang Jahnke Testing of Signal Transduction Inhibitors in Animal Models of Cancer Terence O'Reilly and Robert Cozens Phosphoproteomics in Drug Discovery and Development Michel F. Moran, Jarrod A. Marto, Cynthia J. Brame, Olga Ornatsky, Mark M. Ross, Leticia M. Toledo-Sherman, Alfredo C. Castro, Brett Larsen, Henry Duewel, Christopher Hosfield, Christopher Orsi, Thodoros Topaloglou, Daniel Figeys, Jarrod A. Caldwell-Busby, and David R. Stover Index